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ABSTRACT 
Comparison of children hospitalised with enterovirus (EV) or human parechovirus 
(HPeV) infections of their cerebrospinal fluid (CSF) revealed that HPeV infections presented 
with more persistent fever, irritability and feeding problems, more frequent leukopenia and 
lymphopenia, and higher admission rates to high dependency or intensive care units. As very 
few HPeV cases were followed-up, further studies on long-term outcomes are needed. 
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HIGHLIGHTS 
Children infected with HPeV had more persistent symptoms than those infected with EV 
Children infected with HPeV had higher HDU/ICU admissions than those infected with EV 
Children infected with HPeV had more leukopenia than those infected with EV 
Children infected with EV had higher CSF white cells than those infected with EV 
Further studies are needed to characterise any longer-term EV and HPeV complications 
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INTRODUCTION 
Enteroviruses are well-known causes of sepsis in neonates and infants. In recent 
years, the extent to which parechoviruses may be contributing to neonatal and infant 
morbidity and mortality has begun to emerge.1-3 
Enteroviruses (EV) and human parechoviruses (HPeV) are non-enveloped, single-
stranded, positive-sense RNA viruses and members of the Picornavirus family. They are 
common causes of neonatal and infant sepsis, worldwide.  
Enteroviruses exist as multiple serotypes, subdivided into various genus, including 
echoviruses, Coxsackie A and B viruses, and the numbered enteroviruses. Human 
parechoviruses exist in at least 17 genotypes, of which genotypes 1-6 are most commonly 
found in humans, with genotype 3 being most commonly responsible for sepsis in neonates 
and infants.  
Whilst most episodes of EV and HPeV neonatal and infant sepsis are self-limiting, 
more severe illness can occur and there are current concerns about longer-term sequelae, 
particularly in HPeV infections where there is more significant neurological involvement. 
Previous studies have found that the clinical presentation of the two viruses are often 
indistinguishable.1,3 
Our diagnostic virology laboratory has only relatively recently (since mid-2014) 
introduced routine testing for parechoviruses as part of our neonatal and infant septic work-
up. We examined the demographics, laboratory results and clinical notes for paediatric 
patients admitted with sepsis with laboratory-confirmed human enterovirus (EV) or 
parechovirus (HPeV) infections of the cerebrospinal fluid (CSF), during Feb 2014 to Aug 
2017. 
 
METHODS  
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All cases from a 3.5 year period (Feb 2014 to Aug 2017) were selected on the basis of 
a positive cerebrospinal fluid (CSF) polymerase chain reaction (PCR) result for either EV or 
HPeV RNA, using assays previously described elsewhere,2,4 which were performed as part of 
the routine workup for neonates or infants admitted with suspected sepsis. Additional 
samples were taken depending on the degree of clinical illness, including: EDTA blood, 
rectal swabs or stool samples, and various respiratory samples (nasopharyngeal aspirates, 
throat swabs and bronchoalveolar lavages). For each patient, their laboratory parameters were 
extracted from the laboratory database and clinical notes were reviewed.  
This study was performed as part of a paediatric departmental audit which aimed to 
ensure that all EV and HPeV-infected paediatric patients had received appropriate follow-up 
after discharge for sepsis, where there was laboratory confirmed EV or HPeV infection of the 
CSF. Therefore formal ethics approval was not required. 
Clinical parameters examined included: age at presentation, length of stay, fever, rash, 
seizures, respiratory difficulty, feeding problems, antimicrobial use, and admission to high 
dependency or intensive care units. Laboratory parameters compared included: C-reactive 
protein (CRP), white cell counts (WCC), liver function tests (LFT), CSF profile (glucose, 
protein, and cell counts), and radiological investigations, where available. 
Clinical and laboratory characteristics were compared between patients with HPeV 
and EV infection. Continuous variables were presented as mean and standard deviation (or 
median and interquartile range if not normally distributed) and compared with Student t-test 
(or Wilcoxon test). Binary variables were presented as frequency and percentages, and 
compared with the Fisher Exact test. Multivariable analysis for risk ratios (RR) comparing 
HPeV infection to EV infection as the reference, were estimated using log-Binomial 
regression model. 
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RESULTS 
There were no statistically significant differences in age or sex of the children 
affected by EV vs HPeV CNS infections but there appeared to be a difference in range, with 
EV often affecting older children than HPeV (IQR 29-102 days for EV and 25.5-61 days for 
PeV). 
Out of a total of 163 cases, there were 131 EV (i.e. 7 Coxsackie A, 18 Coxsackie B, 
46 echoviruses, with 60 enteroviruses that could not be typed further) and 32 HPeV 
infections (Table 1). All HPeV infections were caused by HPeV genotype 3 (HPeV-3). Of 
the EV cases, 73% (95 cases) were in children younger than 90 days (3 months), whereas 
over 90% (30 cases) of HPeV cases were in children younger than 90 days (3 months).  
Cases of enterovirus meningitis showed three peaks of activity each year with the 
most significant being in the Nov-Dec period. In contrast, HPeV had only one significant 
outbreak over two months in summer 2016 (Figure S1). There was no difference in the mean 
age or sex of the children affected by EV or PeV, although there was a difference in range, 
with EV meningitis affecting some much older children. 
A greater number of abnormal parameters were found with HPeV than for 
enteroviruses, with a greater likelihood of admission to high dependency unit (HDU)/ 
intensive care unit (ICU) (p=0.004) and a higher rate of persistent symptoms (i.e. fever, 
irritability,and feeding problems, p<0.05) (Table 2). Compared with children infected with 
EV, children with HPeV were more likely to have an abnormally low WCC (leukopenia) 
(56% HPeV vs. 14% EV, p<0.001), and an abnormally low lymphocyte count (lymphopenia) 
(91% HPeV vs. 39% EV, p<0.001) (Table S1).  
In contrast, EV cases were more likely to have a high white cell count in the CSF (6% 
HPeV vs. 50% EV, p<0.001) (Table S1). In the adjusted (log-Binomial regression) analysis, 
the HPeV cases were over 5 more times more likely to have lymphopenia than EV cases 
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(RR=5.11, 95% CI 1.53-17.05, p=0.008), with EV cases being marginally more likely to have 
a higher CSF WCC (RR=0.22, 95% CI 0.05-0.92, p=0.038) (Table S2). 
Other laboratory and clinical parameters, including overall length of stay (LOS) did 
not differ significantly between the EV or HPeV cases, however. There was no significant 
difference in whether or not EV or HPeV cases received antibiotic (98.4% vs. 100%, 
respectively, p=0.999) and/or acyclovir (37.1% vs. 34.4%, respectively, p=0.839) treatment 
(Table 2). 
Finally, relatively few patients were deemed to require longer-term followup. Of the 
total number of cases, 80% of children did not require any follow-up at one year post-
infection. At one year post-infection 3% of children were under follow-up by ophthalmology, 
with no abnormalities detected. Sixteen children (~10%) attended a routine hearing check but 
none had any detectable sensorineural hearing loss. Only 3 patients (<2%) were reported as 
having had any developmental delay problems on admission: 1 child had delayed speech and 
manipulative skills  both of which resolved by one year post-infection. Another child still 
had some speech delay at one year followup, and one child had gross motor delay (despite a 
normal MRI). As 2 of the 3 children with developmental problems had uncomplicated, short 
inpatient stays, this might suggest that their viral infection were not direct causes of this. 
However, this does not completely exclude this aetiological possibility.  
 
DISCUSSION 
Infections by EVs and HPeVs are well-documented causes of neonatal and infant 
sepsis. However relatively few studies have compared the severity of clinical illness caused 
by these viruses within the same paediatric population within the same season.5 
Here we demonstrate differences in presentation and severity of these two viruses, 
with HPeV cases having a higher likelihood of having persistent fevers (p<0.05), irritability 
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or feeding problems (p<0.05), leukopenia, lymphopenia, and requiring admission to HDU or 
PICU than children with EV infections. These findings are consistent with those reported 
from other studies.6-8 In addition, more specifically, Cabrerizo and colleagues9 also noted a 
higher CSF pleocytosis in EV vs. HPeV infections, as found in this study. 
In our population more children aged 30-90 days (n=19, 58%) were infected with HPeV 
than neonates (n =11, 33%). Some studies have found children over the age of 2 months8 or 3 
months9 were unaffected by HPeV, whereas 21% of our cases (7 patients) were diagnosed in 
children aged over 2 months, with 2 cases being in a 4-month and 6-month-old, respectively. 
Thus, routine testing for HPeV in all children with febrile rash illness and sepsis may reveal a 
higher number of older children infected with HPeV.  
Although some previous studies have found pediatric HPeV and EV infections 
clinically indistinguishable,1,3 anecdotally, in our pediatric population, nurses who worked 
with children involved in our recent HPeV outbreak,2  reported that they were able to 
distinguish which children had HPeV rather than EV, prior to any laboratory confirmation, on 
their clinical presentation alone. These HPeV cases were noted to be generally more irritable 
and persistently unconsolable, tachychardic and pyrexial than the more frequently 
encountered annual, seasonal EV cases with which the nurses were very familiar. 
The main limitation of this study is related to the infrequent and sporadic approach to 
the longer-term followup of these EV and HPeV-infected patients, as individual clinical 
teams were left to decide on whether patients being admitted under them warranted such 
admission, as well as prior experiences of the lead paediatrician concerned, rather than any 
local consensus guidelines. 
At present clinical guidelines do not differentiate between the management of 
children presenting with EV versus HPeV infections.3 This study demonstrates that 
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differences in the severity of clinical illness can be seen between the HPeV and EV CNS 
infections, with a greater degree of severity in HPeV cases. Further studies are required to 
clarify and confirm these findings, which may then lead to more practical clinical guidelines 
for the immediate and longer-term management and followup of these patients. 
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Table 1. Specific human enteroviruses (EVs) by type and proportion, identified in the CSF of these 
patients 
 
EVs Number Percentage (%) 
CA16 1 0.76 
CA6 2 1.53 
CA9 4 3.05 
CB1 1 0.76 
CB4 7 5.34 
CB5 10 7.63 
E11 2 1.53 
E16 3 2.29 
E18 7 5.34 
E21 1 0.76 
E25 3 2.29 
E3 1 0.76 
E30 3 2.29 
E5 5 3.82 
E6 4 3.05 
E7 5 3.82 
E71 1 0.76 
E9 10 7.63 
EV7 1 0.76 
Untypeable 60 45.80 
 Total 131 100.00 
 
TABLE 2. Clinical and laboratory characteristics of the EV and HPeV cases 
 
Enterovirus 
(EV) (n=131) 
Parechovirus 
(HPeV) (n=32) 
p-value
Demographics    
Age (days) 50 (29 - 102) 39.5 (25.5 - 61) 0.069 
Sex (female) 42.0% (55/131) 40.6% (13/32) 0.999 
Symptoms 
Fever 94.6% (123/130) 100% (32/32) 0.347 
Peak temperature (oC) 38.5 (0.7) 38.7 (0.7) 0.293 
Feeding problems 56.6% (73/129) 68.8% (22/32) 0.234 
Rash in history 25.2% (32/127) 25.0% (8/32) 0.999 
Seizure 4.7% (6/127) 3.1% (1/32) 0.999 
Respiratory symptoms (coryzal 
symptoms, grunting, cough, wheeze). 35.2% (45/128) 37.5% (12/32) 0.838 
Blood and CSF results 
C-reactive protein (CRP, mg/L) 
(normal range: 0 - 10) 10 (3 - 24) 6 (3 - 13.5) 0.073 
White cell count (WCC, x109/L)  
(normal range: 6.0 - 17.0) 10.5 (4.1) 6.4 (2.9) <0.001 
Neutrophils (x109/L) 
(normal range: 1.50 - 8.50) 5.5 (3.4) 3.7 (2.5) <0.001 
Lymphocytes (x109/L) 
(normal range: 4.00 - 13.50) 4.0 (2.1) 2.0 (0.8) <0.001 
Platelets (x109/L) 
(normal range: 140 - 400) 390.1 (130.0) 353.7 (139.1) 0.165 
Alanine transferase (ALT, IU/L) 23 (18 - 30) 24 (20 - 31) 0.465 
(normal range: 2 - 53) 
Total bilirubin (µmol/L) 
(normal range: 0 - 21) 10.5 (5 - 22) 12 (8 - 32) 0.284 
CSF glucose (mmol/L) 
 2.9 (2.6 - 3.2) 3.1 (2.75 - 3.2) 0.123 
CSF protein (g/L) 
(normal range: 0.10 - 0.45) 0.45 (0.32 - 0.65) 0.39 (0.31 - 0.67) 0.338 
CSF RBC (x106/L) 
(normal range: 0) 8 (2 - 500) 4 (1 - 685) 0.481 
CSF WCC (x106/L) 
(normal range:  0-20) 5 (1 - 75) 1 (0 - 2) <0.001 
CSF %polymorphs* 
(not applicable) 12 (5 - 40) 
CSF %lymphocytes* 
(not applicable) 76.5 (54 - 88) 
CSF taken before antibiotics given 61.9% (78/126) 43.8% (14/32) 0.073 
Treatment and outcome 
Antibiotics given during admission 98.4% (127/129) 100% (32/32) 0.999 
Acyclovir given during admission 37.1% (46/124) 34.4% (11/32) 0.839 
Persistent** pyrexia (first 24-48 hours) 33.1% (42/127) 53.1% (17/32) 0.042 
Persistent** irritability/feeding problem 19.0% (24/126) 37.5% (12/32) 0.034 
At least 1 seizure post antibiotic 
treatment 2.4% (3/127) 6.3% (2/32) 0.264 
Length of stay (LOS, days) 4 (3 - 5) 4 (3 - 5) 0.680 
PICU/HDU 6.1% (8/131) 25.0% (8/32) 0.004 
LOS PICU/HDU***  2 (1 - 5) 2.5 (1 - 4.5) 0.906 
Footnotes: PICU  pediatric intensive care; HDU high dependency unit. 
Continuous data expressed as mean (SD) or median (Q1-Q3) as appropriate, and binary as % (n). 
Missing data - peak temperature (4), WCC (4), platelets (4), neutrophils (5), lymphocytes (5), ALT 
(34), bilirubin (34), CSF protein (2), CSF RBC (3), CSF WCC (3) 
*data available for: 53 patients for CSF %polymorphs; 54 patients for CSF %lymphoctyes 
** -48 hours after treatment commenced 
***PICU/HDU LOS available in 15 patients (7 EV and 8 HPeV)  
